Chemical Namenintedanib
Dosage FormCapsule (oral; 100 mg, 150 mg)
Drug ClassKinase inhibitors
CompanyBoehringer Ingelheim
Approval Year2014


  • For the treatment of idiopathic pulmonary fibrosis (IPF).
  • For the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
  • For the slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Ofev (nintedanib) Prescribing Information.2022Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
Document TitleYearSource
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults.2022American Journal of Respiratory and Critical Care Medicine
German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017.2018Pneumologie (Stuttgart, Germany)